| Literature DB >> 34982550 |
Alister J Cumming1, Diana Khananisho1, Ramona Harris1, Carolyn N Bayer2, Morten H H Nørholm2,3,4, Sara Jamshidi5, Leopold L Ilag5, Daniel O Daley1,3,4.
Abstract
Antibiotic resistance cassettes are indispensable tools in recombinant DNA technology, synthetic biology, and metabolic engineering. The genetic cassette encoding the TEM-1 β-lactamase (denoted Tn3.1) is one of the most commonly used and can be found in more than 120 commercially available bacterial expression plasmids (e.g., the pET, pUC, pGEM, pQE, pGEX, pBAD, and pSEVA series). A widely acknowledged problem with the cassette is that it produces excessively high titers of β-lactamase that rapidly degrade β-lactam antibiotics in the culture media, leading to loss of selective pressure, and eventually a large percentage of cells that do not have a plasmid. To address these shortcomings, we have engineered a next-generation version that expresses minimal levels of β-lactamase (denoted Tn3.1MIN). We have also engineered a version that is compatible with the Standard European Vector Architecture (SEVA) (denoted Ap (pSEVA#1MIN--)). Expression plasmids containing either Tn3.1MIN or Ap (pSEVA#1MIN--) can be selected using a 5-fold lower concentration of β-lactam antibiotics and benefit from the increased half-life of the β-lactam antibiotics in the culture medium (3- to 10-fold). Moreover, more cells in the culture retain the plasmid. In summary, we present two antibiotic-efficient genetic cassettes encoding the TEM-1 β-lactamase that reduce antibiotic consumption (an integral part of antibiotic stewardship), reduce production costs, and improve plasmid performance in bacterial cell factories.Entities:
Keywords: antibiotic stewardship; directed evolution; expression plasmid; genetic cassette; translation initiation region; β-lactamase
Mesh:
Substances:
Year: 2022 PMID: 34982550 PMCID: PMC8787818 DOI: 10.1021/acssynbio.1c00393
Source DB: PubMed Journal: ACS Synth Biol ISSN: 2161-5063 Impact factor: 5.110
Figure 1Commonly used genetic cassettes encoding the TEM-1 β-lactamase. (A) Tn3 fragment from the R1 plasmid of S. paratyphi B (herein called Tn3.1) is 1216 nucleotides long. It contains the bla coding sequence as well as 5′ and 3′UTRs. The 5′UTR contains a P3 promoter and Shine–Dalgarno sequence. Numbers correspond to the AUG start codon of bla. The full sequence of Tn3.1 is shown in Table . (B) Versions of the Tn3.1 fragment that are truncated in the 5′ and 3′ UTR are commonly used (herein called Tn3.2–Tn3.17). These versions may also contain nucleotide substitutions (summarized in Table ). (C) The pSEVA collection contains a codon-varied genetic module encoding the TEM-1 β-lactamase and is flanked by transcriptional terminators and restriction enzyme recognition sites (D). Estimated frequency in the literature of the Tn3-based fragments. Expression plasmids containing the various fragments were searched on Google Scholar, and the number of citations was recorded.
Tn3 Fragments Used in Commercial Expression Plasmidsa
| Tn3.1 | 1–1216 | A | 246 266 | pBR332, pET1*, pET2*, pET3*, pET4*, pET5*, pET6*, pET7*, pET8*, pET11a-d, pET14b, pET15b, pET16b, pET17b, pET19b, pET-DEST42, pET100/D-TOPO, pET100/D-LacZ, pET101/D-LacZ, pET101/D-TOPO, pET102/D-LacZ, pET102/D-TOPO, pET104-DEST, pET104/GW/LacZ, pET104.1-DEST, pET104.1/D/GW-LacZ, pET151/D-TOPO, pET151/D/LacZ, pET160-DEST, pET160/GW/D-TOPO, pET161/GW-CAT, pET300/NT-GW/Ras Kinase, pET300/NT-DEST, pET301/CT-DEST, pET302/NT-his, pGEX-1 lambda T, pGEX-2T, pGEX-2TK, pGEX-3X, pGEX-4T-1, pGEX-4T-2, pGEX-4T-3, pGEX-5X-1, pGEX-6p-1, pGEX-6p-2, pGEX-6p-3 |
| Tn3.2 | 7–1216 | B, C | 116 221 | pGEM-1 pGEM-2, pGEM-4, pGEM-Luc, pUC12, pUC13, pUC18, pUC19, pUC21, pUC57, pUC118, pUC119, pUCX |
| Tn3.3 | 77–1216 | B | 80 658 | pET20b(+), pET21a-d(+), pET22(+), pET23a-d(+), pET25b(+), pET31b(+), pET32a-c(+), pET32 Ek/LIC, pET32 Xa/LIC, |
| Tn3.4 | 76–1216 | B, C | 77 342 | pGEM-5, pGEM-5Zf(+), pGEM-T, pGEM-T easy vector, pGEMT-3P2A, pGEMT-PTE2A |
| Tn3.5 | 6–1216 | B, C | 27 508 | pQE9, pQE16, pQE30, pQE31, pQE32, pQE40, pQE60, pQE70, pQE80-L, pQE81-L. pQE82-L |
| Tn3.6 | 7–1216 | B, C, D | 8930 | pGEM-3Z, pGEM-4Z |
| Tn3.7 | 111–1171 | B, C, O, P | 6688 | pETduet-1, pET43 Ek/LIC, pET43.1a(+), pET44a-c(+), pET45b(+), pET46 Ek/LIC, pET51b(+), pET51 Ek/LIC, pET52(+), pET52 Ek_LIC |
| Tn3.8 | 7–1216 | C to M | 5750 | pGEM-3Zf(+), pGEM-3Zf(−), pGEM-11zf(+), pGEM-11Zf(−), pGEMEX-1, pGEMEX-2 |
| Tn3.9 | 77–1216 | C to M | 3920 | pGEM-7Zf(+), pGEM-7Zf(−) |
| Tn3.10 | 116–1174 | C | 2930 | pBAD24 |
| Tn3.11 | 116–1174 | 2758 | pBAD18, pBAD30, pBAD-bHS, pBAD-EGFP | |
| Tn3.12 | 116–1216 | C | 1601 | pBAD7HisB-iRFP670, pBAD/HisD-TagRFP675, pBAD/Myc-HisA, pBAD/Myc-HisB, pBAD/Myc-HisC, pBAD/gii A, pBAD/gii-B, pBAD/gii-C, pBAD/gii/Calmod, pBAD/HisB |
| Tn3.13 | 77–1216 | B, C | 270 | pGEM-5Zf(−), pGEM-9Zf(−) |
| Tn3.14 | 87–1216 | B | 167 | pET303-CT-His-Rac Kinase, pET303-CT-His |
| Tn3.15 | 13–1216 | B, C, N | 104 | pUCsg-RNA, pUCC001 |
| Tn3.16 | 113–1216 | B | 64 | pBAD-DEST49, pBAD/Myc-His/LacZ, pBAD/D-TOPO |
| Tn3.17 | 113–1161 | O | 23 | pBAD18s |
A: 5′TTCTTGAAGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATGATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTTTAATTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCC-3′.
B: G244 to A mutation in bla (V82 to I).
C: C545 to T mutation in bla (A182 to V); deletion of the PstI site.
D: G553 to C mutation in bla (A185 to P).
E: G226 to C, G227 to A, C228 to T mutations in bla (G76 to H).
F: G229 to A, G231 to A mutations in bla (A77 to T).
G: G232 to C mutation in bla (V78 to L).
H: G244 to A mutation in bla (G82 to H).
I: C275 to G mutation in bla.
J: A276 to G mutation in bla.
K: T277 to C mutation in bla (I93 to A).
L: A278 to G mutation in bla (I93 to A).
M: C281 to G mutation in bla (H94 to R).
N: G717 to T mutation in bla.
O: Nucleotide mutation in 5′UTR (−20 A to C).
P: Nucleotide mutation in 5′UTR (−93 A to C).
Q: Length relative to Tn3.1.
R: Nucleotide sequence of the Tn3.1 fragment is indicated by a B–P. Nucleotide changes from the Tn3.1 fragment are indicated by another letter. Numbering as depicted in Figure A, where the A of the AUG start codon for bla is denoted as +1.
S: Obtained from Google Scholar.
Figure 2Tn3.1MIN reduces levels of the TEM-1 β-lactamase. (A) Illustration of the pET15b-sfgfp expression plasmid, which contains the Tn3.1 fragment. (B) BL21(DE3) harboring the pET15b-sfgfp (Tn3.1) expression plasmid was plated on LB agar containing different concentrations of ampicillin or carbenicillin. Colony numbers were normalized by the number of colonies that grew in the absence of antibiotics. The minimum inhibitory concentration (MIC90) required to kill 90% of cells was extrapolated from the curve (dotted line) and deemed to be approximately 700 μg/mL for ampicillin and >5000 μg/mL for carbenicillin. (C) BL21(DE3) cells (without an expression plasmid) were plated on LB agar containing no antibiotic or 1 μg/mL ampicillin or carbenicillin. As growth was not observed on 1 μg/mL ampicillin or carbenicillin, the MIC90 was deemed to be <1 μg/mL. (D) BL21(DE3) harboring the pET15b-sfgfp expression plasmids plated on LB agar containing different concentrations of ampicillin. The pET15b-sfgfp expression plasmids, denoted C2, B6, D3, and C5, were selected from a directed evolution process and contained Tn3.1 fragments with a different translation initiation region (TIR) for bla. C2 was chosen for further characterization and was named Tn3.1MIN. (E) Nucleotide sequence alignment of the TIR for bla in Tn3.1, Tn3.1MIN (C2), B6, D3, and C5. The TIR is defined as the nucleotide sequence from the Shine–Dalgarno (SD) region through to the fifth codon.[18] (F) As in panel (B) except that BL21(DE3) harbored the pET15b-sfgfp (Tn3.1MIN) plasmid. The MIC90 was deemed to be <30 μg/mL for ampicillin and <200 μg/mL for carbenicillin. (G) Levels of TEM-1 β-lactamase in BL21(DE3) harboring the pET15b-sfgfp expression plasmid (Tn3.1 or Tn3.1MIN), or the culture media, were probed by Western blotting with antisera to the TEM-1 β-lactamase.
Figure 3Tn3.1MIN increases the half-life of ampicillin and carbenicillin in the culture media. (A) Schematic of the experimental workflow used to assess the concentration of ampicillin and carbenicillin in the culture media. Either a single colony or an overnight culture was used to inoculate fresh LB media containing either 100 μg/mL (Tn3.1) or 20 μg/mL (Tn3.1MIN) ampicillin or carbenicillin. Aliquots were analyzed using a semiquantitative mass spectrometry approach. (B) Concentration of ampicillin in the culture media when a single colony of BL21(DE3) harboring pET15b-sfgfp was inoculated. Concentrations are plotted against culture time. (C) As for panel (B) except that an overnight culture was back-diluted 1:100. (D) As for panel (C) except that carbenicillin was used.
Figure 4Tn3.1MIN helps cells to maintain the plasmid. (A) Schematic representation of the experimental workflow for determining the percentage of cells with a plasmid. This was determined by calculating the relative ratio of colonies on LB agar plates, with or without ampicillin selection. (B) Percentage of BL21(DE3) harboring pET15b-sfgfp (Tn3.1). In cultures with and without ampicillin, most cells maintained a plasmid after 20 h of cultivation. (C) After induction of sfGFP with IPTG, the majority of BL21(DE3) did not have the pET15b-sfgfp (or Tn3.1) plasmid. (D) As for panel (C) except that the pET15b-sfgfp (or Tn3.1MIN) plasmid was used. Here a larger proportion of cells in the culture harbored the plasmid. Data presented as mean ± standard deviation (s.d.) (n ≥ 3).
Figure 5Tn3.1MIN prevents contamination. (A) Schematic representation of the experimental workflow for determining whether contaminants can survive after back-dilution. Supernatants from overnight cultures of BL21(DE3) harboring pET15b-sfgfp were back-diluted in the presence of a contaminant; BL21(DE3) harboring pET28a-mcherry. Growth of the contaminant was monitored by cell density. (B) Growth of the contaminant was monitored in LB media containing ampicillin (100 μg/mL for Tn3.1 or 20 μg/mL for Tn3.1MIN). The contaminant could grow when Tn3.1 was used but not Tn3.1MIN. (C) As for panel (B) except that ampicillin was omitted in the back-dilution. This control indicates that the contaminant can always grow in the absence of ampicillin, when the supernatants are present. (D) As for panel (B) except that the supernatants were omitted in the back-dilution. This control indicates that the contaminants cannot grow in the presence of ampicillin.
Figure 6Characterization of Ap (pSEVA#1MIN--). (A) MC1061 cells harboring the pSEVA191 or pSEVA191 plasmid were spotted on LB agar plates with different concentrations of ampicillin. For comparison, BL21(DE3) harboring the pET15b-sfgfp (Tn3.1 and Tn3.1MIN) expression plasmid was also spotted. When Ap (pSEVA#1--) and Tn3.1 were used, cells could survive on 1000 μg/mL of ampicillin. When Ap (pSEVA#1MIN--) and Tn3.1MIN were used, cells could only survive on 20 μg/mL of ampicillin. (B) MC1061 cells (without an expression plasmid) were plated on LB agar containing 0, 1, 2, and 3 μg/mL ampicillin. As growth was not observed on 3 μg/mL ampicillin, the MIC90 was deemed to be <3 μg/mL. (C) Levels of TEM-1 β-lactamase were probed by Western blotting with antisera to the TEM-1 β-lactamase. β-Lactamase could only be observed when Ap (pSEVA#1--) and Tn3.1 were used. (D) Collection of pSEVA plasmids with Ap (pSEVA#1--) and different origins of replication were transformed into MC1061 cells and spotted on LB agar plates with different concentrations of ampicillin. For comparison, BL21(DE3) harboring the pET15b-sfgfp (Tn3.1) expression plasmid was also spotted. “L” denotes a low copy, “M” a medium copy, and “H” a high copy plasmid. (E) As in panel (D) except that all pSEVA vectors contained Ap (pSEVA#1MIN--) and pET15b-sfgfp contained Tn3.1MIN.